An open ended equity scheme investing in Pharma and Healthcare Services Sector



Market Market Investment Objective

The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes' objectives will be achieved.

Fund Manager

Mr. Dhaval Shah & Mr. Dhaval Joshi

Date of Allotment

July 11, 2019

Benchmark

S&P BSE Healthcare TRI

Managing Fund Since

July 11, 2019 & November 21, 2022

Experience in Managing the Fund

4.1 Years & 0.7 Years

Monthly: Minimum ₹ 500/-

⁰ Fund Category

Thematic (Equity)



PARTNER (S) EASYLINE CLICK HERE %



Load Structure (as % of NAV) (Incl. for SIP)

Entry Load Nil Fxit Load

For redemption/switchout of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment:

Monthly Average AUM	₹	500.14	Crores
AUM as on last day	₹	523.47	Crores

Гotal Ex	nanca	Patio (TED

Regular	2.44%
Direct	1.09%
Including additional expenses and good	ods and service tax on management

Other Parameters	
Standard Deviation	15.03%
Sharpe Ratio	0.50
Beta	0.94
Portfolio Turnover	0.38

Note: Standard Deviation, Sharpe Ratio & Beta are calculated on Annualised basis using 3 years history of monthly returns.

Risk Free Rate assumed to be 6.6% (FBIL Overnight MIBOR as on 31 July 2023) for calculating Sharpe Ratio

Application Amount for fresh subscription

₹ 1,000 (plus in multiplies of ₹ 1)

Min. Addl. Investment

₹ 1,000 (plus in multiplies of ₹ 1)

PORTFOLIO


Issuer	% to Net Assets	Rating
Pharmaceuticals & Biotechnology	79.75%	
Sun Pharmaceutical Industries Limited	14.45%	
Cipla Limited	7.15%	
Torrent Pharmaceuticals Limited	6.76%	
Aurobindo Pharma Limited	6.60%	
Dr. Reddys Laboratories Limited	4.67%	
Zydus Lifesciences Limited	4.20%	
Lupin Limited	3.81%	
Alkem Laboratories Limited	3.70%	
J.B. Chemicals & Pharmaceuticals Limited	2.94%	
Biocon Limited	2.94%	
Abbott India Limited	2.38%	
ALEMBIC PHARMACEUTICALS LIMITED	2.38%	
Strides Pharma Science Limited	2.32%	
Ajanta Pharmaceuticals Limited	2.32%	
Gland Pharma Limited	2.32%	
Natco Pharma Limited	2.28%	
Sanofi India Limited	2.24%	

Issuer	% to Net Assets	Rating
Mankind Pharma Ltd	2.16%	
Eris Lifesciences Limited	2.14%	
Granules India Limited	1.01%	
Indoco Remedies Limited	1.01%	
Healthcare Services	15.72%	
Apollo Hospitals Enterprise Limited	7.31%	
Fortis Healthcare Limited	4.81%	
Global Health Ltd/India	1.29%	
Vijaya Diagnostic Centre Limited	1.24%	
Syngene International Limited	1.08%	
Chemicals & Petrochemicals	1.30%	
Vinati Organics Limited	1.30%	
Retailing	1.22%	
Medplus Health Services Limited	1.22%	
Food Products	0.82%	
Zydus Wellness Limited	0.82%	
Cash & Current Assets	1.18%	
Total Net Assets	100.00%	


_				
Investment Performance	NAV as on July 31, 2023: ₹ 20.6100			
Inception - July 11, 2019	Since Inception	5 Years	3 Years	1 Year
Aditya Birla Sun Life Pharma & Healthcare Fund	19.50%	NA	14.11%	20.40%
Value of Std Investment of ₹ 10,000	20,610	NA	14,859	12,053
Benchmark - S&P BSE Healthcare TRI	22.04%	NA	15.66%	22.04%
Value of Std Investment of ₹ 10,000	22,454	NA	15,470	12,217
Additional Benchmark - Nifty 50 TRI	15.62%	NA	22.71%	16.18%
Value of Std Investment of ₹ 10,000	18,029	NA	18,479	11,628

Value of Std Investment of ₹ 10,000	18,029	NA	18,479	11,628			
Past performance may or may not be sustained in future. The above performance is of Regular Plan - Growth Option. Kindly note that different plans have different expense structure. Load and Taxes are not considered for computation of returns. When scheme/additional benchmark returns are not available, they							
different expense structure. Load and lakes are not considered for computation or returns. When scheme/additional benchmark returns are not available, they have not been shown. Total Schemes Co-Managed by Fund Managers is 1. Total Schemes managed by Mr. Dhaval Shah is 5. Total Schemes managed by Mr. Dhaval Shah is 5. Total Schemes managed by Mr.							
Dhaval Joshi is 45. Refer annexure on page no. 164-165 to know more on performance of schemes managed by Fund Managers.							

Note: The exit load (if any) rate levied at the time of redemption/switch-out of units will be the rate prevailing at the time of allotment of the corresponding units. Customers may request for a separate Exit Load Applicability Report by calling our toll free numbers 1800-270-7000 or from any of our Investor Service



\$Income Distribution cum capital withdrawal



An open ended equity scheme investing in Pharma and Healthcare Services Sector



SIP Performance - Regular Plan - Growth (assuming SIP of ₹ 10000 per month)						
Particulars	Since Inception	5 years	3 years	1 Year		
Total Amount Invested (₹)	490000	NA	360000	120000		
Market Value of amount Invested	681297	NA	433237	143551		
Scheme Returns (CAGR)	16.30%	NA	12.43%	38.50%		
S&P BSE Healthcare TRI# (CAGR)	18.77%	NA	13.79%	39.44%		
Nifty 50 TRI## (CAGR)	18.23%	NA	16.41%	20.90%		

Date of First Installment: August 01, 2019 & Scheme Inception Date: July 11, 2019. Past Performance may or may not be sustained in future. # Scheme Benchmark, ## Additional Benchmark

For SIP calculations above, the data assumes the investment of ₹ 10000/- on 1st day of every month or the subsequent working day. Load & Taxes are not considered for computation of returns. Performance for IDCW option would assume reinvestment of tax free IDCW declared at the ner prevailing NAV. CAGR returns are computed after accounting for the cash flow by using XIRR method (investment internal rate of return). Where Benchmark returns are not available, they have not been shown. Past performance may or may not be sustained in future. Returns greater than 1 year period are compounded annualized. IDCW are assumed to be reinvested and bonus is adjusted. Load is not taken into consideration. For SIP returns, monthly investment of equal amounts invested on the 1st day of every month has been considered.

